Back to Search
Start Over
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
- Source :
- Plus Company Updates. November 11, 2023
- Publication Year :
- 2023
-
Abstract
- MARLBOROUGH: Phio Pharmaceuticals Corp. has issued the following press release: Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLtm RNAi platform technology is designed to make [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.773796017